Sign in

    Christopher Uhde

    Senior Pharma & Biotech Equity Analyst at SEB

    Christopher Uhde is a Senior Pharma & Biotech Equity Analyst at SEB, specializing in Nordic and European biotechnology and pharmaceutical companies, with a strong track record advising on successful IPOs and private placements. He has been involved in raising significant capital for leading firms, such as overseeing a €50 million placement at a €500 million valuation for an advanced Swedish regenerative medicine platform, and is recognized for his deep expertise in assessing public and private biotech opportunities. With a career rooted in pharmaceutical research and investment banking, Christopher leverages a scientific background—including a PhD—and experience across dynamic market cycles to help innovative companies scale and access capital markets. He is known for providing thought leadership on market trends and holds advanced finance and scientific credentials, though specific FINRA or securities licenses are not publicly listed.

    Christopher Uhde's questions to Alvotech (ALVO) leadership

    Christopher Uhde's questions to Alvotech (ALVO) leadership • Q2 2025

    Question

    Christopher Uhde of SEB inquired about Alvotech's confidence in its full-year 2025 guidance, the potential for further growth from the Cymlandi (Humira biosimilar) Qualant channel in the U.S., and whether the company plans to issue press releases on FDA inspection outcomes for its late-stage pipeline candidates.

    Answer

    CFO Linda Jónsdóttir stated that while H1 was strong, the company is not changing its guidance due to expected revenue lumpiness, with Q3 being soft and Q4 being much stronger. CCO Anil Okay added that the Qualant channel business is expected to continue, but the focus is on value over volume. CEO Róbert Wessman explained that FDA inspections are a normal part of business and the company will inform the market upon product approvals rather than after each inspection.

    Ask Fintool Equity Research AI